초록

Materials and methods for treating certain cancers are described, preferably cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and more preferably chronic myelogenous leukemia, and which cancer is preferably resistant to the inhibition of the Bcr-Abl tyrosine kinase, imatinib.

대표청구항 ▼

We claim: 1. A method for treating a patient suffering from cancer, wherein said patients' cancer exhibits up-regulation of the RAF-MEK-ERK pathway, comprising administering to the cancer patient an effective dose of an inhibitor of said RAF-MEK-ERK pathway, wherein said cancer is CML, and said inh

We claim: 1. A method for treating a patient suffering from cancer, wherein said patients' cancer exhibits up-regulation of the RAF-MEK-ERK pathway, comprising administering to the cancer patient an effective dose of an inhibitor of said RAF-MEK-ERK pathway, wherein said cancer is CML, and said inhibitor is selected from the group consisting of Bay 43-9006 and CI-1040. 2. The method of claim 1, wherein said CML is resistant to an inhibitor of Bcr-Abl tyrosine kinase. 3. The method of claim 2, wherein said inhibitor of Bcr-Abl tyrosine kinase is imatinib. 4. The method of claim 2, wherein said inhibitor of the RAF-MEF-ERK pathway is Bay 43-9006. 5. The method of claim 2, wherein said inhibitor of the RAF-MEF-ERK pathway is CI-1040. 6. The method of claim 1, further comprising administering an inhibitor of Bcr-Abl tyrosine kinase. 7. The method of claim 6, wherein said inhibitor of the RAF-MEF-ERK pathway is Bay 43-9006. 8. The method of claim 6, wherein said inhibitor of the RAF-MEF-ERK pathway is CI-1040.